Delivery Order SPE2DB22D2206-SPE2DB25FEF07

Award Date 11/13/24
Potential Completion Date 12/5/24
Potential Value $178K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Revlimid 15 mg capsules. The contract is a Delivery Order with a Firm Fixed Price pricing type, a ceiling value of $37,445.14, and a performance period ending on May 9, 2025. The contract is not set aside for any particular business category. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This federal contract award is for the delivery of the pharmaceutical drug Revlimid (10 mg capsule, 28-count) to the Defense Logistics Agency (DLA). The $23,330.28 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The contract, which has no set-aside designation, has a completion date of June 5, 2024. AmerisourceBergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $77,433.35, is for the delivery of Revlimid 25 mg capsules. It is a firm-fixed-price delivery order contract with an ultimate completion date of August 29, 2022. The contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $178,310.12, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of REVLIMID 10 MG CAPSULE 100S, a medical product, with an ultimate completion date of February 4, 2025. The contract is a Firm Fixed Price arrangement and does not have a set-aside designation. AmerisourceBergen holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The $27,599.94 firm fixed price delivery order is for the supply of Revlimid 5 mg capsules. The order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. This IDC...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $199,707.28, is a delivery order for the supply of REVLIMID 10 MG CAPSULE 28S, a prescription medication. The contract is a firm fixed-price, non-set-aside award with a performance period through May 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,963.40 firm fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of March 11, 2025 and was awarded on February 18, 2025. This appears to be a task order under a larger Indefinite Delivery Contract (IDC) that...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Revlimid 10 mg capsules. The contract has a ceiling value of $49,926.80 and a performance period ending on May 23, 2025. The contract is a firm-fixed-price delivery order, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,963.40, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 5 MG CAPSULE 28S. The contract has an ultimate completion date of January 22, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award is a delivery order with a ceiling value of $24,963.40 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, with a period of performance through November 2024. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition....
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FEF07
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $178,310.12, is a delivery order for the supply of 10 mg Revlimid capsules. The contract has a firm fixed-price pricing type and an ultimate completion date of December 5, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 2/12/25, 9:12 AM